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both groups, but IG patients showed an earlier control
(61.8% control in IG vs 36.4% in CG at 12 weeks; p =
0.038). 2) INFONET Program: The ﬁrst 250 SMS were
analysed. Percentages of SMS sent by physicians were:
support (50.3%), Therapeutic compliance (2.7%),
Asking for data (29.5%), Scheduling visits to surgery
(6.0%), Modifying medication (1.6%), Others (9.9%).
The most frequent scheduling was one SMS every 12
days. CONCLUSIONS: In the usual practice (INFONET
Program), physicians use the SMS system in a different
way than predicted (HTA-Alert). They tend to give
support and to ask for data, instead of addressing com-
pliance and life-habits messages. Frequency of messages
was also lower. The use of SMSs seems to be a useful tool
for educational programs, and it would be convenient to
explore in more detail its effectiveness in health outcomes.
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IMPROVED COMPLIANCE AND PERSISTENCE
WITH ATORVASTATINE THROUGH A
PHARMACY-BASED INTERVENTION
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OBJECTIVES: To establish the effect of a pharmaceuti-
cal care program on compliance and persistence with
once-daily atorvastatine treatment in patients with ele-
vated cholesterol levels. METHODS: An open-label,
prospective controlled trial of 1-year duration was con-
ducted in Belgium, stratiﬁed by language region. A French
speaking and a Flemish speaking region were randomized
to a Measurement Guided Medication Management
(MGMM) intervention consisting of review by the
patients’ pharmacist of the electronically compiled dosing
history, a “beep-card” that reminds patient of the dosing
time and educational reminders. The control group
received care as usual, also stratiﬁed between the 2
regions. Compliance was measured in all patients using
the Medication Event Monitoring System (MEMS®,
AARDEX, Switzerland), deﬁned as the % doses taken as
prescribed (once-daily). Nonpersistence was deﬁned as
the % of patients who stopped using atorvastatine before
the end of the study. Because of the skewed nature of
compliance data, statistical reporting includes medians,
25–75% interquartile ranges, and non-parametric tests.
RESULTS: A total of 393 patients were included: inter-
vention group: n = 194, control group: n = 199. After 1-
year follow-up and stratiﬁcation by region, the median %
of doses taken as prescribed (25% quartile–75% quartile)
was 96.1 (92.7–98.2) in the intervention group versus
89.9 (77.1–95.6) in the control group (p < 0.0001). Other
compliance variables showed similar results % prescribed
doses taken: 98.9 (96.3–100.3) vs 95.2 (83.0–98.9), p <
0.001, % doses within prescribed interval ±25%: 92.8
(85.9–95.9) vs 84.4 (63.0–92.5), p < 0.001 and Thera-
peutic Coverage: 96.1 (92.9–97.8) vs 93.6 (84.6–96.6), 
p < 0.001. Persistence was signiﬁcantly better in the inter-
vention group: 87.1% vs 76.9% in the control group 
(p = 0.02). Explanatory analysis showed that the Flemish
patient group and an elevated cardiovascular risk score
were signiﬁcantly related to better compliance and per-
sistence. CONCLUSIONS: Measurement Guided Med-
ication Management improved patient compliance and
persistence with atorvastatine.
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OBJECTIVE: Troponin T levels (TnT) predict hard
ischemic events and prognosis in patients (p) with unsta-
ble angina (UA) or non ST-segment elevation myocardial
infarction (NSTEMI). There are no reports on their
ability to predict the development of heart failure (HF) in
that population. METHODS: In order to determine the
ability of TnT to predict the incidence of NYHA class III
or IV HF along three months after an episode of unsta-
ble UA or NSTEMI, TnT levels were measured to 352 p
between the ﬁfth and 24th hour from hospital admission
due to an acute episode attributable to such diagnosis,
being 231 men and 121 women, mean age 67.6 years
(range 20 to 88). Personal or phone interview of patients
or relatives were obtained three months after the acute
episode looking for signs or symptoms of advanced heart
failure. RESULTS: TnT levels were higher than or equal
to 0.1ng/ml in 135p (TnT+ group) and less than 
0.1ng/ml in the other 217p (TnT- group). Both groups
were comparable in age (69 vs 66) and slightly different
in proportion of women (42% vs 32%). Three patients
died after episodes of class IV HF and all three pertained
to the TnT+ group. Odds ratios (OR) and their 95% con-
ﬁdence intervals (Cl) for the development of class III or
IV HF are reﬂected in the table. CONCLUSIONS:
Patients admitted with the diagnosis of unstable angina
or non ST-segment elevation myocardial infarction have
much more episodes of advanced heart failure in the fol-
lowing three months when Troponin T levels are elevated
in the ﬁrst 24 hours of the acute ischemic episode. TnT+
TnT- n(%) n(%) OR 95%CI p NYHA III/IV 11(8.9)
5(2.4) 3.85 1.3–11.3 < 0.03 NYHA IV 7(5.5) 2(0.9) 5.88
1.2–28.7 < 0.05.
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OBJECTIVE: The aim of the study was to evaluate the
effect of the angiotensin receptor blocker eprosartan on
pulse pressure as well as to identify those factors inﬂu-
encing such effect. METHODS: Observational, multicen-
ter study performed in hypertensive patients attending
primary care centers. Patients completed 12 weeks of
treatment with eprosartan. Blood pressure was measured
by means of a validated oscillometric device (OMRON
705CP) provided with a printer at beginning of treatment
and at 4, 8, and 16 weeks. RESULTS: After 16 weeks,
3133 patients out of 4067 completed treatment (87% in
monotherpy), mean age of 67 years (55% women). Com-
ponents of blood pressure decreased: systolic blood pres-
sure from 165.9 ± 15.5mm Hg dyastolic from 93.5 ± 10.4
to 80.6 ± 8.3mmHg, mean blood pressure from 117 ±
9.3mmHg to 100.1 ± 9.03mmHg, pulse pressure from
72.5 ± 16.9mmHg, PP decrease at 16th week was 4%
higher to the decrease in MBP. The effect was more 
pronounced in older patients, those with higher basal
PP/MBP and with target organ damage. Among adverse
events reported, 35% affected to digestive system. CON-
CLUSIONS: Eprosartan is an effective and well tolerated
antihypertensive drug able to reduce PP. This reduction is
partially independent of the severity of high blood pres-
sure. This aspect may be important in terms of safety and
target organ protection.
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OBJECTIVES: Heart Failure (HF) is the leading cause 
of hospitalization and re-admission in many hospitals
worldwide. A number of small randomized trials have
attempted to determine whether multi-disciplinary dis-
charge programs aimed speciﬁcally at educating patients
can reduce rates readmission and mortality rates. This
meta-analysis evaluates the effectiveness of peri-
discharge, multidisciplinary HF management programs.
METHODS: We identiﬁed studies through an electronic
search of 4 bibliographical databases, our own ﬁles, ref-
erences lists, the Cochrane review database, consultation
with experts, reference lists, abstracts from meetings,
interviews with authors and tracked down unpublished
studies and studies in progress. Eligible studies met the
following criteria: Randomized controlled clinical trials
of adult inpatients hospitalized for heart failure enrolled
at the peri-discharge transition period offered HF-speciﬁc
patient education intervention coupled with a post-
discharge follow-up assessment that reported unplanned
readmission or mortality. For each study we determined
the eligibility using a checklist that we developed through
consensus and the quality using the Jadad (ref). Four
authors independently assessed each study for eligibility
agreement was rated using a weighted Kappa. For each
study we calculated a relative risk ratio for readmissions
and mortality for patients receiving enhanced education
(Intervention) relative to patients receiving usual care
(Control). RESULTS: A total of 529 citation titles were
identiﬁed of which 8 randomized trials proved eligible.
The pooled risk ratio (RR) for hospital readmission rates
using a random effects model was 0.77, 95% conﬁdence
interval CI 0.68–0.84, p < 0.001 with a non-signiﬁcant
test for heterogeneity 0 = 0.25. There was no apparent
effect on mortality, RR 0.0.98 CI 0.0.72–1.34, p = 0.9,
with a non-signiﬁcant test for heterogeneity p = 0.2. There
was insufﬁcient data to meaningfully pool intervention
effects on quality of life or compliance. CONCLUSION:
This systematic review suggests that speciﬁc heart failure
interventions targeted at the discharge transition period
signiﬁcantly decrease hospital readmissions.
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OBJECTIVE: Evaluate the effectiveness of self-
measurement of blood pressure as a tool for hypertensive
patient education to improve control of hypertension.
METHODS: One hundred eighty Primary Care Units
(PCU) were randomized to two groups: 86 applied the
intervention (I) and 94 collected data on Usual Clinical
Practice (UCP). A medical doctor and a nurse composed
all PCU. Patients included had Diastolic Blood Pressure
(DBP) and Systolic Blood Pressure (SBP) above the rec-
ommended control levels (140/90mmHg). Intervention
consisted in provide OMRON HEM705CP blood pres-
sure measurer to the patients during two visits: between
the 6th and 8th week and the 14th and 16th week after
the inclusion into the study. OMRON was recommended
to be used during 15 days and was gave a handbook to
the patients to register the results of self-measurements
and delivered to the physician in the next visit. Blood
pressure at PCU was measured in each visit (baseline, and
6, 8, 14, 16, and 24 week). The main criteria for effec-
tiveness measurement was proportion of patients with
DBP and SBP < 140/90mm Hg or <130/85 in diabetic
patients. RESULTS: A total of 1325 patients (622 I, 703
UCP) with similar demographic characteristics were
included by the 180 PCU. At week 8, the proportion of
patients with blood pressure levels well controlled was
higher in I group in 7.6% (p = 0.01) than UCP group.
Nevertheless, differences among the groups were reduced
to 4.1% favorably I vs. UPC (p = 0.27). At the end of the
study (24th week) the difference in terms of effectiveness
